Cerulean Pharma Inc. (Nasdaq: CERU) reported disappointing results from a Phase 2 study of CRLX101 sending the stock price plummeting $1.54 to close at $1.20.
Disappointing study results for Cerulean Pharma
August 18, 2016 at 17:17 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.